Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 20/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.51 |
| ▸ | PDE1A | P54750 | 10/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 10/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 10/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.51 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.49 |
| ▸ | PDE5A | O76074 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299557 | 1.00 | PDE7A (0.51) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL299164 | 0.99 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL29408521 | 0.99 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL2680184 | 0.90 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL29408499 | 0.90 | PDE7A (0.53) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL13237032 | 0.89 | PDE7A (0.39) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL29408483 | 0.89 | PDE7A (0.55) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL299935 | 0.89 | PDE7A (0.55) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL299383 | 0.85 | PDE7A (0.50) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL29408489 | 0.85 | PDE7A (0.50) | PDE7APDE4DPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| US-20220062194-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORP (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062194-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE4D 7/4885PDE1A 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.